VIVUS Inc. (VVUS)

4.29
NASDAQ : Health Technology
Prev Close 4.17
Day Low/High 4.14 / 4.31
52 Wk Low/High 2.15 / 5.78
Avg Volume 115.60K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 44.38M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Vivus Weight-Loss Drug's Failing Math

Vivus Weight-Loss Drug's Failing Math

The launch of Vivus' obesity pill Qsymia has been disappointing to date.

Biotech Stock Live Chat

Biotech Stock Live Chat

TheStreet columnist Adam Feuerstein takes your biotech investing questions.

Biotech Stock Mailbag: Ziopharm, Sarepta, Vivus, Aegerion, Gilead

Biotech Stock Mailbag: Ziopharm, Sarepta, Vivus, Aegerion, Gilead

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

7 Stocks Rising on Big Volume

7 Stocks Rising on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Cramer: ADP Report is Irrelevant

Cramer: ADP Report is Irrelevant

Jim Cramer says we should throw out the ADP report and the BLS should out source the work to TIBCO.

Biotech Stock Mailbag: Pending Sarepta Results, Cyclacel

Biotech Stock Mailbag: Pending Sarepta Results, Cyclacel

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

Weight Loss Pills Not a Threat, Says Medifast CEO

Weight Loss Pills Not a Threat, Says Medifast CEO

Mike MacDonald, CEO of Medifast, says the company's new franchise strategy is propelling its stock and recently approved weight loss pills are not a threat.

Higher Prices Favored

This market should have broken during the summer, but it didn't and there are now multiple tailwinds.

Cramer's 'Mad Money' Recap: No Day of Reckoning

Cramer's 'Mad Money' Recap: No Day of Reckoning

The market's problems are more like a laundry list of things that must be done rather than a great unknown waiting to destroy us all, Cramer said

Vivus Beats Arena Pharma With Obesity Drug Launch

Vivus Beats Arena Pharma With Obesity Drug Launch

Vivus' Qsymia still faces questions about pricing compared to generics.

The Next Big Thing in Biotech: Obesity Drugs

The Next Big Thing in Biotech: Obesity Drugs

Senior columnist Adam Feuerstein says obesity drugs are the next big thing to watch in biotech.

The Essential 2012 Biotech Stock Fall Preview

The Essential 2012 Biotech Stock Fall Preview

If you're a biotech investor not following these stocks this fall, you're not paying attention.

2012 Biotech Stock Predictions: An Interim Report Card

2012 Biotech Stock Predictions: An Interim Report Card

Check out the accuracy of the 2012 biotech sector predictions made by Adam Feuerstein

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

The Next Big Thing in Biotech: FDA Approvals

The Next Big Thing in Biotech: FDA Approvals

Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.

Six Must-Follow Earnings for Aug. 7

Six Must-Follow Earnings for Aug. 7

Sirius XM Radio and Walt Disney are among the widely followed companies that report earnings on Tuesday.

<I>TheStreet</I> Readers Make Perfect Predictions in Drug-Approval Contest

TheStreet Readers Make Perfect Predictions in Drug-Approval Contest

Eleven contestants correctly predicted all five FDA events.

Amarin Insiders Rush to Sell Stock One Day After Fish-Oil Pill Approval

Amarin Insiders Rush to Sell Stock One Day After Fish-Oil Pill Approval

The timing of Amarin's insider sales are unsettling given the questions that linger over Vascepa's future.

Biotech Stock Mailbag: Amarin, Sarepta

Biotech Stock Mailbag: Amarin, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Horizon Pharma: Rayos FDA Approval Thursday Seems Likely

Horizon Pharma: Rayos FDA Approval Thursday Seems Likely

Horizon will sell Rayos as a morning pain relief for patients with rheumatoid arthritis.

Top 5 Must-Follow Earnings for Monday

Top 5 Must-Follow Earnings for Monday

Monday promises a full day of surprises and disappointments. These are the most likely to move the market.

Amarin: Prepping for FDA Approval Decision

Amarin: Prepping for FDA Approval Decision

A primer on all you need to know as Amarin waits on FDA's decision to approve its prescription fish oil pill.

Biotech Stock Mailbag: Peregrine Pharma

Biotech Stock Mailbag: Peregrine Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

TheStreet Quant Rating: D (Sell)